Top Updates Back
BrightPath Bio Co., Ltd.
ブライトパス・バイオ株式会社
BrightPath Biotherapeutics Co., Ltd. Alias
2003-05-08
4594
TYO
Japan
7F, Kojimachi Central Building, 2-2-4 Kojimachi, Chiyoda-ku, Tokyo
Kenichi Nagai
1,199,000,000 JPY　(11 100 millionJPY)
24 people
24 people
Company name
Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
三菱UFJ信託銀行株式会社
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Bank

17 entries
DateDescription
2003-05-08 Company established at 67 Asahi-cho, Kurume City, Fukuoka Prefecture (capital 10,000 thousand yen)
2006-01 Initiated Phase I clinical trial of ITK-1 for castration-resistant prostate cancer.
2011-11 Entered into an exclusive license agreement with Fujifilm Holdings Corporation regarding ITK-1.
2013-06 Initiated Phase III clinical trial of ITK-1 for castration-resistant prostate cancer.
2015-06 The interim analysis of the Phase III clinical trial of ITK-1 for castration-resistant prostate cancer indicated a promising likelihood of achieving the primary endpoint in the final analysis, and the efficacy and safety assessment committee recommended continuing the trial as planned.
2015-10 Initiated Phase I clinical trial of GRN-1201 for melanoma (malignant melanoma) in the United States.
2015-10 Listed on the Tokyo Stock Exchange Mothers.
2016-08 Established the Kawasaki Pharmaceutical Research Institute in the Tonemachi area of Kawasaki City, Kanagawa Prefecture.
2017-01 Initiated Phase II clinical trial of GRN-1201 in combination with immune checkpoint inhibitors for non-small cell lung cancer in the United States.
2017-07 Changed company name to BrightPath Bio Co., Ltd.
2018-04 Participated in RIKEN's iPSC-derived regenerative NKT cell therapy development project.
2018-05 Conducted key opening of the Phase III clinical trial of ITK-1 for castration-resistant prostate cancer patients.
2019-05 Discontinued development of ITK-1.
2019-06 Relocated head office to 25-22, Tonemachi 3-chome, Kawasaki-ku, Kawasaki City, Kanagawa Prefecture.
2020-06 Initiated physician-led clinical trial of iPS-NKT cell therapy.
2022-05 Initiated physician-led clinical trial of HER2 CAR-T cell therapy (BP2301).
2022-05 Announced early termination of the Phase II clinical trial of GRN-1201 in the United States.
+ Loaded when opened
8290001050314
Trade nameブライトパス・バイオ株式会社
Trade name (kana)ブライトパスバイオ
Name in English
Corporation type301
Address〒210-0821 神奈川県川崎市川崎区殿町３丁目２５番２２号
Postal code2100821
Prefecture code14
City code131
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date2015-10-05
Update date2019-07-23
Change date2019-07-18
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record1
Excluded from search0
Processing type12
Correction type0
Trade name image ID
Address image ID
Sequence number2937666
Source: National Tax Agency Corporate Number Publication Site, basic three items
8290001050314
Corporate number8290001050314
Trade nameブライトパス・バイオ株式会社
Trade name (kana)ブライトパスバイオ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address神奈川県川崎市川崎区殿町３丁目２５番２２号
Postal code2100821
Prefecture神奈川県
Prefecture code14
City or district川崎市川崎区
City code131
Street address殿町３丁目２５番２２号
Organisation type301
Processing type12
Correction type0
Status
Representative代表取締役社長　永井 健一
Capital1199869000
Employees24
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date2019-07-23
Key information8290001050314
Source: gBizINFO (Ministry of Economy, Trade and Industry)
✅
2026-09-23 01:56 (Model: ggml-org/gpt-oss-20b )
↑